IRIS Accounts Production v25.1.0.734 12593299 Board of Directors 1.1.24 31.3.25 31.3.25 10/7/2025 0 true false true false false true false Auditors Opinion iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh125932992023-12-31125932992025-03-31125932992024-01-012025-03-31125932992022-12-31125932992023-01-012023-12-31125932992023-12-3112593299ns15:EnglandWales2024-01-012025-03-3112593299ns14:PoundSterling2024-01-012025-03-3112593299ns10:Director12024-01-012025-03-3112593299ns10:PrivateLimitedCompanyLtd2024-01-012025-03-3112593299ns10:SmallEntities2024-01-012025-03-3112593299ns10:Audited2024-01-012025-03-3112593299ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012025-03-3112593299ns10:SmallCompaniesRegimeForAccounts2024-01-012025-03-3112593299ns10:FullAccounts2024-01-012025-03-3112593299ns10:Director42024-01-012025-03-3112593299ns10:RegisteredOffice2024-01-012025-03-3112593299ns5:CurrentFinancialInstruments2025-03-3112593299ns5:CurrentFinancialInstruments2023-12-3112593299ns5:ShareCapital2025-03-3112593299ns5:ShareCapital2023-12-3112593299ns5:SharePremium2025-03-3112593299ns5:SharePremium2023-12-3112593299ns5:RetainedEarningsAccumulatedLosses2025-03-3112593299ns5:RetainedEarningsAccumulatedLosses2023-12-3112593299ns5:CostValuation2023-12-3112593299ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-3112593299ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-31
REGISTERED NUMBER: 12593299 (England and Wales)















FINANCIAL STATEMENTS FOR THE PERIOD 1 JANUARY 2024 TO 31 MARCH 2025

FOR

DECIPHERA PHARMACEUTICALS (UK) LIMITED

DECIPHERA PHARMACEUTICALS (UK) LIMITED (REGISTERED NUMBER: 12593299)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE PERIOD 1 JANUARY 2024 TO 31 MARCH 2025




Page

Company information 1

Balance sheet 2

Notes to the financial statements 3


DECIPHERA PHARMACEUTICALS (UK) LIMITED

COMPANY INFORMATION
FOR THE PERIOD 1 JANUARY 2024 TO 31 MARCH 2025







Directors: J Larson
M Ostrovsky





Registered office: Suite 2 First Floor
10 Temple Back
Bristol
United Kingdom
BS1 6FL





Registered number: 12593299 (England and Wales)





Auditors: Hayvenhursts Limited
Fairway House
Links Business Park
St Mellons
Cardiff
CF3 0LT

DECIPHERA PHARMACEUTICALS (UK) LIMITED (REGISTERED NUMBER: 12593299)

BALANCE SHEET
31 MARCH 2025

2025 2023
Notes £ £
FIXED ASSETS
Investments 4 5 5

CURRENT ASSETS
Debtors 5 7,919 1,007
Cash at bank 162,300 43,155
170,219 44,162
CREDITORS
Amounts falling due within one year 6 (174,103 ) (47,184 )
NET CURRENT LIABILITIES (3,884 ) (3,022 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(3,879

)

(3,017

)

CAPITAL AND RESERVES
Called up share capital 2 2
Share premium 4 4
Retained earnings (3,885 ) (3,023 )
SHAREHOLDERS' FUNDS (3,879 ) (3,017 )

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 8 July 2025 and were signed on its behalf by:





J Larson - Director


DECIPHERA PHARMACEUTICALS (UK) LIMITED (REGISTERED NUMBER: 12593299)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD 1 JANUARY 2024 TO 31 MARCH 2025

1. STATUTORY INFORMATION

Deciphera Pharmaceuticals (UK) Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The Company's functional and presentational currency is pound sterling (£) and the financial statements have been rounded to the nearest pound (£).

The financial statements have been prepared for the period 1 January 2024 to 31 March 2025. The financial accounting period has been extended to align with the fiscal year of its new parent, along with practical considerations regarding the process for implementing that change. As a result the comparative amounts presented are not entirely comparable.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern
These financial statements have been drawn up on the going concern basis. The company is dependent upon the support of its parent company, in order to meet its working capital requirements. The parent company has provided assurances that this support will continue for a period that exceeds twelve months from the date of approval of these financial statements and believes it will have the funds required to provide this support.

On the basis of the assurances received form the parent company the directors believe that the going concern basis is appropriate. No adjustments have been made in these accounts which might result from that uncertainty.

Preparation of consolidated financial statements
The financial statements contain information about Deciphera Pharmaceuticals (UK) Limited as an individual Company and do not contain consolidated financial information as the parent of a group. The Company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Turnover
Turnover represents amounts charged to the Company's parent under an agreement for marketing and other services provided, excluding value added tax. Turnover is recognised when chargeable costs are incurred. The subcontracting, third-party or foreign exchange costs incurred by the Company in the provision of the services are passed through the Company's parent without applying any mark-up.

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost less any provision for impairment.

DECIPHERA PHARMACEUTICALS (UK) LIMITED (REGISTERED NUMBER: 12593299)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 1 JANUARY 2024 TO 31 MARCH 2025

2. ACCOUNTING POLICIES - continued

Financial instruments
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into.

Basic financial liabilities
Basic financial liabilities, including creditors, and loans from fellow group companies are initially recognised at transaction price.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are initially recognised at transaction price.

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 3 (2023 - NIL ) .

DECIPHERA PHARMACEUTICALS (UK) LIMITED (REGISTERED NUMBER: 12593299)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 1 JANUARY 2024 TO 31 MARCH 2025

4. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£
Cost
At 1 January 2024
and 31 March 2025 5
Net book value
At 31 March 2025 5
At 31 December 2023 5

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2023
£ £
Other debtors 7,919 1,007

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2023
£ £
Trade creditors 8,758 -
Amounts owed to group undertakings 104,607 45,189
Taxation and social security 8,919 -
Other creditors 51,819 1,995
174,103 47,184

7. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the auditors was unqualified.

Gareth R Williams (Senior Statutory Auditor)
for and on behalf of Hayvenhursts Limited

8. ULTIMATE PARENT COMPANY

The immediate parent undertaking of the company is Deciphera Pharmaceuticals (Netherlands) B.V., (incorporated in Netherlands)

Ono Pharmaceutical Co., Ltd (incorporated in Japan) is regarded by the directors as being the company's ultimate parent company.

The largest and smallest group in which the results of the company are consolidated is headed by Ono Pharmaceutical Co., Ltd, incorporated in Japan. Consolidated financial statements for Ono Pharmaceutical Co., Ltd, are available on the company website www.ono-pharma.com.